flonoltinib
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 12, 2021 (NCT05115344)
Timeline
Indications
Mechanism of action
FLT3 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07232290 | Phase 2 | Sep 23, 2025 | China Academy of Chinese Medical Sciences, Government of China, Shengjing Hospital, Sichuan University |
| NCT07193576 | Phase 1 | Aug 4, 2024 | Government of China, Huazhong University of Science and Technology |
| NCT06457425 | Phase 2 | May 6, 2024 | Chinese Academy of Medical Sciences, Government of China, Sichuan University |
| NCT06387966 | Phase 1 | Feb 29, 2024 | Government of China, Huazhong University of Science and Technology |
| NCT05153343 | Phase 1 | Dec 6, 2021 | Government of China, Sichuan University |
| NCT05115344 | Phase 1 | Nov 12, 2021 | Government of China, Sichuan University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 6 | 6 | 2 | 2021 |
| Sichuan University | Academic/Hospital | 4 | 0 | 2 | 2021 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 0 | 1 | 2024 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Shengjing Hospital | Academic/Hospital | 1 | 0 | 1 | 2025 |
6 organizations
Page 1 / 1